Sun Pharma reported 2.56% year-on-year (YoY) increase in its consolidated net profit at Rs 3,117.95 crore in Q2FY26 from Rs 3,040.16 crore in Q2FY25.
The pharmaceutical major reported revenue from operations at Rs 14,478.31 crore against Rs 13,291.39 crore in Q2FY25.
Key highlights from Sun Pharma Q2FY26
On sequential basis the company reported 36.83% jump in consolidated net profit and 4.53% surge in revenue.
EBITDA stood at Rs. 4,527.1 crore, up 14.9% and EBITDA margin recorded at 31.3%. The company noted that the R&D investment was Rs. 782.7 crore that is 5.4% of sales.
The Q2 release highlights that formulation sales in India were Rs. 4,734.8 crore, registering a growth of 11%. India Formulation sales accounted for 32.9% of total consolidated sales for the quarter.
Sun Pharma has been focusing on building a stronger portfolio of innovative drugs across dermatology, oncology, and obesity therapies, as it targets a mid-to-high single-digit revenue growth for the current fiscal year.
Sales from its global innovative drug segment — a high-margin business that includes treatments for conditions such as alopecia and psoriasis — grew 16.4% to $333 million. Notably, sales of innovative medicines in the US surpassed those of generics for the first time in the quarter, according to managing director Kirti Ganorkar.
However, overall US sales, the company’s second-largest revenue contributor, fell 4.1% to $496 million. Indian generic drugmakers, including Sun Pharma, continue to face pricing pressure in the US market due to intense competition, which has weighed on profit margins.
